The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study
Abstract
Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants provide real benefits and whether tricyclic and selective serotonin reuptake inhibitor (SSRI) antidepressants differ in their short‐term efficacy, because the time to onset of therapeutic benefit remains an important criterion in depression. The short‐term efficacy (after 14 and 30 days) of two antidepressants (desipramine, a predominantly noradrenergic reuptake inhibitor tricyclic and citalopram, a SSRI) was assessed in a double‐blind, randomized, placebo‐ controlled study of 48 nondemented PD patients suffering from major depression. After 14 days, desipramine prompted an improvement in the Montgomery Asberg Depression Rating Scale (MADRS) score, compared with citalopram and placebo. Both antidepressants produced significant improvements in the MADRS score after 30 days. Mild adverse events were twice as frequent in the desipramine group as in the other groups. A predominantly noradrenergic tricyclic antidepressant induced a more intense short‐term effect on parkinsonian depression than did an SSRI. However, desipramine's lower tolerability may outweigh its slight short‐term clinical advantage. © 2008 Movement Disorder Society
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Diagnostic and Statistical Manual of Mental Disorders (DSM-IV)
Hu, R. J. (2003) · Encyclopedia of the Neurological Sciences · doi:10.1016/b0-12-226870-9/01070-4 · Cited by 9,117
Rank transformations as a bridge between parametric and nonparametric statistics
Conover, W. J., & Iman, R. L. (1981) · The American Statistician · doi:10.1080/00031305.1981.10479327 · Cited by 3,922
The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Diagnostic Criteria for Parkinson Disease
Gelb, D. J., Oliver, E., & Gilman, S. (1999) · Archives of Neurology · doi:10.1001/archneur.56.1.33 · Cited by 2,822
Depression and Parkinson's disease: a review
(1992) · American Journal of Psychiatry · doi:10.1176/ajp.149.4.443 · Cited by 1,111
Remy, P., Doder, M., Lees, A., Turjanski, N., & Brooks, D. (2005) · Brain · doi:10.1093/brain/awh445 · Cited by 1,040
Depression rating scales in Parkinson's disease: Critique and recommendations
Schrag, A., Barone, P., Brown, R. G., Leentjens, A. F. G., McDonald, W. M., Starkstein, S., Weintraub, D., Poewe, W., Rascol, O., Sampaio, C., et al. (2007) · Movement Disorders · doi:10.1002/mds.21333 · Cited by 683
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
Chan‐Palay, V., & Asan, E. (1989) · Journal of Comparative Neurology · doi:10.1002/cne.902870308 · Cited by 495
Reduced Levels of Norepinephrine Transporters in the Locus Coeruleus in Major Depression
Klimek, V., Stockmeier, C., Overholser, J., Meltzer, H. Y., Kalka, S., Dilley, G., & Ordway, G. A. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-21-08451.1997 · Cited by 445
The Occurrence of Depression in Parkinson's Disease: A Community-Based Study
Tandberg, E. (1996) · Archives of Neurology · doi:10.1001/archneur.1996.00550020087019 · Cited by 409
Marsh, L., McDonald, W. M., Cummings, J., Ravina, B., & NINDS/NIMH Work Group on Depression and Parkinson's Disease (2006) · Movement Disorders · doi:10.1002/mds.20723 · Cited by 318
Leentjens, A. F. G., Verhey, F. R. J., Lousberg, R., Spitsbergen, H., & Wilmink, F. W. (2000) · International Journal of Geriatric Psychiatry · doi:10.1002/1099-1166(200007)15:7<644::aid-gps167>3.0.co;2-l · Cited by 278
Selective Serotonin-Reuptake Inhibitor–Induced Movement Disorders
Gerber, P. E., & Lynd, L. D. (1998) · Annals of Pharmacotherapy · doi:10.1345/aph.17302 · Cited by 267
What contributes to depression in Parkinson's disease?
SCHRAG, A., JAHANSHAHI, M., & QUINN, N. P. (2001) · Psychological Medicine · doi:10.1017/s0033291799003141 · Cited by 242
Antidepressant studies in Parkinson's disease: A review and meta‐analysis
Weintraub, D., Morales, K. H., Moberg, P. J., Bilker, W. B., Balderston, C., Duda, J. E., Katz, I. R., & Stern, M. B. (2005) · Movement Disorders · doi:10.1002/mds.20555 · Cited by 191 · cited 1×
“7% Desipramine – 0% 0% Overall Hamilton Anxiety Rating Scale score Placebo 18 [15,22] 10 [9,14] 10 [9,12] Citalopram 18 [14,21] 10 [6,13] 6 [4,9] Desipramine 20 [19,25] 11 [11,16] 8 [7,10]”
Brain serotonin transporter binding in non‐depressed patients with Parkinson's disease
Guttman, M., Boileau, I., Warsh, J., Saint‐Cyr, J. A., Ginovart, N., McCluskey, T., Houle, S., Wilson, A., Mundo, E., Rusjan, P., et al. (2007) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.01727.x · Cited by 187
The application of anticipatory avoidance learning to the treatment of homosexuality
Feldman, M. P., & MacCulloch, M. J. (1964) · Behaviour Research and Therapy · doi:10.1016/0005-7967(64)90013-0 · Cited by 173
A survey of antidepressant drug use in Parkinson's disease
Richard, I. H., Kurlan, R., & Parkinson Study Group (1997) · Neurology · doi:10.1212/wnl.49.4.1168 · Cited by 169
Imaging in Parkinson’s Disease: The Role of Monoamines in Behavior
Brooks, D. J., & Piccini, P. P. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.12.017 · Cited by 151
Bordet, R., Thomas, P., & Dupuis, B. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.10.1346 · Cited by 124
Self-citationEhrt, U., Brønnick, K., Leentjens, A. F. G., Larsen, J. P., & Aarsland, D. (2006) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1456 · Cited by 118
Therapies for depression in Parkinson's disease
Ghazi‐Noori, S., Chung, T. H., Deane, K. H., Rickards, H. E., & Clarke, C. E. (2003) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003465 · Cited by 117
DESIPRAMINE IN TREATMENT OF PARKINSON'S DISEASE
Laitinen, L. V. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1969.tb01224.x · Cited by 109
Imipramine in Treatment of Parkinsonism: a Double-blind Placebo Study
Strang, R. R. (1965) · BMJ · doi:10.1136/bmj.2.5452.33 · Cited by 104
Vizi, E. S., Zsilla, G., Caron, M. G., & Kiss, J. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1506-04.2004 · Cited by 95
Ekselius, L., von Knorring, L., & Eberhard, G. (1997) · International Clinical Psychopharmacology · doi:10.1097/00004850-199711000-00005 · Cited by 92
Norepinephrine involvement in antidepressant action.
Frazer, A. (2000) · PubMed · Cited by 89
Valentini, V., Frau, R., & Chiara, G. D. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02238.x · Cited by 81
A three-factor model of the MADRS in major depressive disorder
Suzuki, A., Aoshima, T., Fukasawa, T., Yoshida, K., Higuchi, H., Shimizu, T., & Otani, K. (2005) · Depression and Anxiety · doi:10.1002/da.20058 · Cited by 79
Åberg-Wistedt, A., Ross, S. B., Jostell, K., & Sjöquist, B. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00914.x · Cited by 75
Pharmacology of antidepressants: selectivity or multiplicity?
Westenberg, H. G. M. (1999) · PubMed · Cited by 73
A three‐factor analytic model of the MADRS in geriatric depression
Parker, R., Flint, E. P., Bosworth, H. B., Pieper, C. F., & Steffens, D. C. (2002) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.776 · Cited by 71
Systematic review of antidepressant therapies in Parkinson's disease.
Chung, T. H., Deane, K. H. O., Ghazi-Noori, S., Rickards, H., & Clarke, C. (2003) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(03)00108-1 · Cited by 66
The Serotonergic Hypothesis for Depression in Parkinson's Disease: an Experimental Approach
Leentjens, A. F. G., Scholtissen, B., Vreeling, F. W., & Verhey, F. R. J. (2005) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300914 · Cited by 52
Depression in Parkinson’s Disease
Pfeiffer, R. F., Wszolek, Z. K., & Ebadi, M. (2004) · CRC Press eBooks · doi:10.1201/9780203508596-41 · Cited by 38
Åberg‐Wistedt, A., Ross, S. B., Jostell, K. ‐., & Sjöquist, B. (1982) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1982.tb00915.x · Cited by 20
Valentini, V., Cacciapaglia, F., Frau, R., & Chiara, G. D. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03030.x · Cited by 19
Cited by
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Depression in Parkinson disease—epidemiology, mechanisms and management
Aarsland, D., Påhlhagen, S., Ballard, C. G., Ehrt, U., & Svenningsson, P. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.189 · Cited by 593
Barone, P., Poewe, W., Albrecht, S., Debieuvre, C., Massey, D., Rascol, O., Tolosa, E., & Weintraub, D. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70106-x · Cited by 562
Neuropsychiatric symptoms in Parkinson's disease
Aarsland, D., Marsh, L., & Schrag, A. (2009) · Movement Disorders · doi:10.1002/mds.22589 · Cited by 557
Metadata
- Authors
- Devos, D., Dujardin, K., Poirot, I., Moreau, C., Cottencin, O., Thomas, P., Destée, A., Bordet, R., & Defebvre, L.
- Venue
- Movement Disorders
- Publisher
- Wiley
- Published
- 2008-04-24
- Volume
- 23
- Issue
- 6
- Pages
- 850-857
- ISSN
- 0885-3185 (ISSN-L)
- 1531-8257
- OpenAlex
- W2110790733
- Cited by
- 274
- References
- 40
- FWCI
- 14.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.